Related Experiment Video
Updated: May 27, 2026
10:25
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Acute-on-chronic liver failure in chronic hepatitis B
Wai-Kay Seto1, Ching-Lung Lai, Man-Fung Yuen
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
Journal of Gastroenterology and Hepatology
|November 22, 2011
Summary
Acute-on-chronic liver failure (ACLF) in chronic hepatitis B (CHB) has high mortality and poorly understood causes. Liver transplantation offers definitive treatment, but better prognostication is needed for timely intervention.
Area of Science:
- Hepatology
- Virology
- Critical Care Medicine
Background:
- Chronic hepatitis B (CHB) can progress to acute-on-chronic liver failure (ACLF), a severe condition.
- The exact mechanisms driving ACLF in CHB patients are not fully elucidated.
- ACLF in CHB is characterized by high mortality rates despite available treatments.
Purpose of the Study:
- To review the current understanding of ACLF pathophysiology in CHB.
- To discuss predisposing factors and prognostic markers for ACLF in CHB.
- To evaluate treatment strategies and future directions for managing ACLF in CHB.
Main Methods:
- Literature review of studies on ACLF in chronic hepatitis B.
- Analysis of predisposing factors, prognostic markers, and therapeutic interventions.
- Discussion of the role of nucleoside analog therapy and liver transplantation.
Main Results:
- Acute severe exacerbation is the primary cause of ACLF in CHB.
- Nucleoside analog therapy has shown limited survival benefits in most studies.
- Liver transplantation is the only definitive treatment for ACLF in CHB.
Conclusions:
- ACLF in CHB presents significant challenges due to high mortality and complex pathophysiology.
- Accurate prognostication is crucial for guiding treatment decisions, including early liver transplantation.
- Further prospective research is essential to refine management strategies and improve patient outcomes.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...